Singapore, Sept. 23 -- US-basedRevvity, Inc.has announced a strategic collaboration withProfluent, also based in the US, bringing together a range of its novel artificial intelligence (AI)-engineered enzymes with Revvity's establishedPin-pointTMbase editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit.

This new Pin-point configuration allows for increased precision and efficiency, with some combinations being precise to single nucleotide edits without bystander editing.

Additionally, the Pin-point platform's modular design has shown delivery of ultra-low amounts of deaminase while maintaining clinically-relevant levels of base editing and reducing off-target activity, which l...